AR116483A1 - Inhibidores de egfr de quinazolina - Google Patents

Inhibidores de egfr de quinazolina

Info

Publication number
AR116483A1
AR116483A1 ARP190102695A ARP190102695A AR116483A1 AR 116483 A1 AR116483 A1 AR 116483A1 AR P190102695 A ARP190102695 A AR P190102695A AR P190102695 A ARP190102695 A AR P190102695A AR 116483 A1 AR116483 A1 AR 116483A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
substituted
alkoxy
hydroxy
Prior art date
Application number
ARP190102695A
Other languages
English (en)
Inventor
Prasad V Chaturvedula
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of AR116483A1 publication Critical patent/AR116483A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente documento describe una clase de inhibidores de EGFR de quinazolina. También se describen composiciones farmacéuticas de estos y un método para tratar cánceres. Reivindicación 1: Un compuesto o una sal farmacéuticamente aceptable de este, caracterizado porque el compuesto está representado por la fórmula (1) en donde: R¹ es hidrógeno, alquilo C₁₋₆ o alquilo C₁₋₆ sustituido con alcoxi C₁₋₆ o un grupo heterocíclico de 5 ó 6 miembros que tiene al menos uno seleccionado del grupo que consiste en N, O y S; R² es hidrógeno, -COOH, alquiloxicarbonilo C₁₋₆ o amido N no sustituido o N-sustituido con Y; Y es hidroxi o alquilo C₁₋₆ o alquilo C₁₋₆ sustituido con Z; Z es hidroxi, alcoxi C₁₋₃, alquiltio C₁₋₃, alquilsulfonilo C₁₋₃, di-alquilamina C₁₋₃, alquilo C₁₋₆, fenilo o un grupo heterocíclico aromático o no aromático de 5 ó 6 miembros, donde dicho grupo heterocíclico contiene de uno a cuatro del resto seleccionado del grupo que consiste en N, O, S, SO y SO₂ y dicho grupo arilo y heterocíclico no está sustituido o está sustituido con sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, amino, nitro, ciano, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, monoalquilamino C₁₋₆ y dialquilamino C₁₋₆; A es NH, o alquilo NC₁₋₆alquilo cuando X es CH; alternativamente, A es nulo cuando X es N o NH; B es un resto de fórmula (2) ó (3), en donde: R³, R⁴, R⁵ y R⁶ se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, halógeno, N-C₁₋₆ alquil o N-hidroxiamido o C-C₁₋₆ alquil amido inverso (-NHCOC₁₋₆), hidroxicarbonilo (-COOH), alquiloxicarbonilo C₁₋₆ (-COOC₁₋₆), alquilo C₁₋₆ y alquilo C₁₋₆ sustituido con un hidroxi, di-alquilamina C₁₋₆ o un grupo heterocíclico de 3 a 6 miembros que tiene al menos uno seleccionado del grupo que consiste de N, O y S, en donde el grupo heterocíclico de 5 o 6 miembros no está sustituido o está sustituido con alquilo C₁₋₄; E se selecciona del grupo que consiste en: los restos de fórmula (4) ó (5), y un anillo bicíclico de 9 a 12 miembros, en donde cada uno de estos está opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxi, cieno, nitro, (mono-, di- o trihalógeno)metilo, mercapto, alquiltio C₁₋₆, acrilamido, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, feniloxi y dialquilamino C₁₋₆, además, en donde M se selecciona del grupo que consiste en O, S, NH, alquilo NC₁₋₆ y alquilo C₁₋₆; y a y b son cada uno un número entero en el intervalo de 0 a 6, con la condición de que a y b no sean simultáneamente 0.
ARP190102695A 2018-09-21 2019-09-23 Inhibidores de egfr de quinazolina AR116483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734655P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
AR116483A1 true AR116483A1 (es) 2021-05-12

Family

ID=69887926

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102695A AR116483A1 (es) 2018-09-21 2019-09-23 Inhibidores de egfr de quinazolina

Country Status (10)

Country Link
US (1) US20210353627A1 (es)
EP (1) EP3852762A4 (es)
JP (1) JP2022501344A (es)
KR (1) KR20210066841A (es)
CN (1) CN113056272A (es)
AR (1) AR116483A1 (es)
CA (1) CA3112198A1 (es)
TW (1) TW202023563A (es)
UY (1) UY38384A (es)
WO (1) WO2020061470A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201333A1 (en) 2020-11-11 2022-05-19 Bayer Aktiengesellschaft N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
CN115803326B (zh) * 2020-11-23 2024-03-26 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
WO2023213882A1 (en) 2022-05-04 2023-11-09 Bayer Aktiengesellschaft Irreversible mutegfr inhibitors
WO2024028316A1 (en) 2022-08-02 2024-02-08 Bayer Aktiengesellschaft 1h-pyrrolo[3,2-b]pyridine derivatives as irreversible inhibitors of mutant egfr for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
WO2004013091A2 (en) * 2002-08-01 2004-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
MXPA06003607A (es) * 2003-10-16 2006-06-05 Chiron Corp Quinazolinas, quinoxalinas, quinolinas e isoquinolinas 2.6-disubstituidas como inhibidores de la cinasa raf para el tratamiento del cancer.
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
AU2017363199B2 (en) * 2016-11-17 2023-08-17 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
AR113451A1 (es) * 2017-10-18 2020-05-06 Spectrum Pharmaceuticals Inc Inhibidores de tirosina quinasas de la familia de los egfr mutantes
CN108299398B (zh) * 2018-04-27 2021-04-02 广州富瑞价值医疗健康产业有限公司 一种具有抗肿瘤活性含咔唑的喹唑啉衍生物及其制药用途

Also Published As

Publication number Publication date
CA3112198A1 (en) 2020-03-26
TW202023563A (zh) 2020-07-01
US20210353627A1 (en) 2021-11-18
JP2022501344A (ja) 2022-01-06
KR20210066841A (ko) 2021-06-07
CN113056272A (zh) 2021-06-29
WO2020061470A1 (en) 2020-03-26
UY38384A (es) 2020-04-30
EP3852762A1 (en) 2021-07-28
EP3852762A4 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
AR116483A1 (es) Inhibidores de egfr de quinazolina
AR121044A1 (es) Inhibidores de egfr
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR110003A2 (es) Derivado de amida
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
AR062666A1 (es) Benzotriazoles como moduladores de quinasas
AR107966A2 (es) Derivados de pirimidina y piridina inhibidores de la proteína quinasa
AR110405A1 (es) Compuestos
AR109560A1 (es) Compuestos moduladores de receptores tipo toll
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR091400A2 (es) Composicion farmaceutica que comprende derivados de sulfamida, proceso para prepararla y uso de dichos compuestos para preparar medicamentos
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
AR037485A1 (es) Uso de un compuesto derivado de pirazol-triazina en la fabricacion de un medicamento, medicamento que comprende un compuesto derivado de pirazol-triazina, producto industrial y composicion farmaceutica
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
AR119657A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
AR044956A1 (es) Derivados de pirrolodihidroisoquinolinas, composiciones farmaceuticas que los contienen y su uso en el tratamiento del cancer.
AR115871A1 (es) MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
BRPI0519288A2 (pt) compostos heterocÍclicos como antagonistas de ccr2b
AR123779A1 (es) Método para preparar l-glufosinato
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
AR114369A1 (es) Dinucleótidos cíclicos como agentes antineoplásicos
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR098871A1 (es) Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa